NEW YORK, December 29, 2025, 22:17 ET — Market closed
- Gilead Sciences shares were last up about 0.2% at $124.91 after Monday’s session.
- Bernstein reiterated an Outperform rating, saying Medicaid “most-favored-nation” pricing risk looks contained for Gilead’s biggest HIV product, Biktarvy. Investing.com
- Investors are watching for more details on the Trump administration’s drug-pricing rollout and Gilead’s next investor update at the J.P. Morgan Healthcare Conference in January.
Gilead Sciences (GILD.O) shares were last up 0.15% at $124.91 on Monday, as investors weighed an analyst note that argued new Medicaid drug-pricing rules would have a limited financial impact on the company’s HIV franchise.
The call matters now because drugmakers and investors are still parsing a Trump administration pricing push that targets Medicaid and aims to bring U.S. medicine prices closer to those in other wealthy countries.
For Gilead, the focus has been on whether “most-favored-nation” pricing — a policy that effectively ties prices to lower international benchmarks — could pressure margins for its biggest products that rely heavily on U.S. government reimbursement. Reuters+1
Bernstein said in a note on Monday that only about 60% of Gilead’s brands would align with most-favored-nation pricing for Medicaid under the new arrangement, and that Biktarvy appeared to face “minimal” Medicaid risk. Investing.com
The firm said the primary products affected were older HIV therapies Genvoya and Odefsey, which it pegged at roughly $750 million in Medicaid gross spend in 2023 — spending before rebates and discounts are applied.
Bernstein estimated the 2026 revenue impact from the Medicaid change at less than $200 million for Genvoya and Odefsey combined, a low single-digit percentage impact for the total company, according to the note.
The analyst focus follows agreements announced earlier this month in which President Donald Trump and a group of major drugmakers, including Gilead, agreed to cut prices for some medicines sold into Medicaid and to consumers paying cash, while also committing to “most-favored-nation” pricing for future drug launches. Reuters
Those agreements included other large U.S. and European peers such as Merck, Bristol Myers Squibb and Amgen, tying the policy risk across the sector to a single political and regulatory backdrop rather than company-specific fundamentals.
Bernstein analyst Courtney Breen said at the time the deals were designed to “deliver headlines and minimize any step-change” in company economics. Reuters
Gilead’s move came as the broader U.S. market pulled back from last week’s rally, with heavyweight technology stocks weighing on the major indexes.
Before the next session, traders will be watching whether Gilead can hold above Monday’s low of $124.20 and challenge the day’s high near $125.11, levels that have started to frame near-term support and resistance.
Investors also have a date on the calendar: Gilead is scheduled to appear at the J.P. Morgan Annual Healthcare Conference on Jan. 12, 2026, with a webcast listed at 2:15 p.m. ET.
The next major catalyst after that is earnings season. Nasdaq lists Gilead’s next earnings report as expected on Feb. 10, 2026, an event where investors are likely to look for updated guidance and any quantified read-through from Medicaid pricing changes.
